Increased sales of new products, better profit margins and internal restructuring and integration have been cited as reasons for pharma major GlaxoSmithKline (LSE: GSK) reporting strong first-quarter growth for 2016.
The UK’s biggest pharma company reports that its sales have risen by 8% during the quarter, with £6.2 billion ($9 billion) raised, generating core earnings per share of 19.8 pence.
GSK has declared a dividend of 19 pence for the quarter and continues to expect to pay a full year dividend of 80 pence for 2016 and for 2017.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze